evertex fabrinology limited (TPE:1470)
22.50
+0.40 (1.81%)
May 29, 2026, 1:30 PM CST
TPE:1470 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 781.07 | 803.71 | 788.04 | 655.22 | 845.15 | 894.79 | |
Revenue Growth (YoY) | -3.78% | 1.99% | 20.27% | -22.47% | -5.55% | 41.86% |
Cost of Revenue | 580.08 | 609.31 | 588.66 | 525.4 | 670.83 | 703.67 |
Gross Profit | 200.99 | 194.4 | 199.38 | 129.82 | 174.32 | 191.12 |
Selling, General & Admin | 110.33 | 110.76 | 111.59 | 96.62 | 105.93 | 112.68 |
Operating Expenses | 110.18 | 110.89 | 112.02 | 96.47 | 105.94 | 112.65 |
Operating Income | 90.81 | 83.51 | 87.37 | 33.35 | 68.38 | 78.47 |
Interest Expense | -0.79 | -0.83 | -0.95 | -0.9 | -0.56 | -0.48 |
Interest & Investment Income | 13.26 | 14.13 | 14.74 | 9.4 | 8.21 | 4.44 |
Currency Exchange Gain (Loss) | -17.39 | -17.39 | 17.03 | -1.18 | 13.35 | -3.03 |
Other Non Operating Income (Expenses) | 4.98 | 2.82 | 1.66 | 1.69 | 1.73 | -0.56 |
EBT Excluding Unusual Items | 90.87 | 82.24 | 119.85 | 42.36 | 91.11 | 78.83 |
Gain (Loss) on Sale of Investments | 0.41 | 0.41 | 0.33 | 13.73 | -41.11 | -1.22 |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | 0.52 | 1.09 | - | 1.14 |
Other Unusual Items | - | - | 0 | - | 0.01 | - |
Pretax Income | 91.29 | 82.66 | 120.7 | 57.18 | 50 | 78.75 |
Income Tax Expense | 17 | 15.4 | 23.39 | 7.83 | 17.16 | 13.55 |
Net Income | 74.28 | 67.27 | 97.31 | 49.35 | 32.84 | 65.2 |
Net Income to Common | 74.28 | 67.27 | 97.31 | 49.35 | 32.84 | 65.2 |
Net Income Growth | -13.52% | -30.88% | 97.20% | 50.25% | -49.63% | 84.11% |
Shares Outstanding (Basic) | 86 | 86 | 86 | 86 | 86 | 86 |
Shares Outstanding (Diluted) | 86 | 86 | 86 | 86 | 86 | 86 |
Shares Change (YoY) | 0.24% | -0.05% | 0.09% | 0.00% | -0.05% | 0.06% |
EPS (Basic) | 0.86 | 0.78 | 1.13 | 0.58 | 0.38 | 0.76 |
EPS (Diluted) | 0.86 | 0.78 | 1.13 | 0.57 | 0.38 | 0.76 |
EPS Growth | -14.00% | -30.97% | 98.25% | 50.00% | -50.00% | 85.37% |
Free Cash Flow | 63.39 | 62.06 | 85.02 | 110.62 | 162.2 | -1.32 |
Free Cash Flow Per Share | 0.74 | 0.72 | 0.99 | 1.29 | 1.89 | -0.01 |
Dividend Per Share | 0.650 | 0.650 | 1.010 | 0.580 | 0.450 | 0.800 |
Dividend Growth | -35.64% | -35.64% | 74.14% | 28.89% | -43.75% | 90.48% |
Gross Margin | 25.73% | 24.19% | 25.30% | 19.81% | 20.63% | 21.36% |
Operating Margin | 11.63% | 10.39% | 11.09% | 5.09% | 8.09% | 8.77% |
Profit Margin | 9.51% | 8.37% | 12.35% | 7.53% | 3.89% | 7.29% |
Free Cash Flow Margin | 8.12% | 7.72% | 10.79% | 16.88% | 19.19% | -0.15% |
EBITDA | 131.12 | 126.22 | 133.64 | 79.95 | 116.99 | 130.4 |
EBITDA Margin | 16.79% | 15.71% | 16.96% | 12.20% | 13.84% | 14.57% |
D&A For EBITDA | 40.31 | 42.71 | 46.27 | 46.6 | 48.61 | 51.93 |
EBIT | 90.81 | 83.51 | 87.37 | 33.35 | 68.38 | 78.47 |
EBIT Margin | 11.63% | 10.39% | 11.09% | 5.09% | 8.09% | 8.77% |
Effective Tax Rate | 18.62% | 18.63% | 19.38% | 13.70% | 34.31% | 17.20% |
Revenue as Reported | 781.07 | 803.71 | 788.04 | 655.22 | 845.15 | 894.79 |